Author | Eshleman, Susan H. | |
Author | Fogel, Jessica M. | |
Author | Halvas, Elias K. | |
Author | Piwowar-Manning, Estelle | |
Author | Marzinke, Mark A. | |
Author | Kofron, Ryan | |
Author | Wang, Zhe | |
Author | Mellors, John | |
Author | McCauley, Marybeth | |
Author | Rinehart, Alex R. | |
Author | Clair, Marty St | |
Author | Adeyeye, Adeola | |
Author | Hinojosa, Juan C. | |
Author | Cabello, Robinson | |
Author | Middelkoop, Keren | |
Author | Hanscom, Brett | |
Author | Cohen, Myron S. | |
Author | Grinsztejn, Beatriz | |
Author | Landovitz, Raphael J. | |
Access date | 2024-04-22T03:02:26Z | |
Available date | 2024-04-22T03:02:26Z | |
Document date | 2022 | |
Citation | ESHLEMAN, Susan H. et al. HIV RNA Screening Reduces Integrase Strand Transfer Inhibitor Resistance Risk in Persons Receiving Long-Acting Cabotegravir for HIV Prevention. The Journal of Infectious Diseases, v. 226, n. 12, p. 2170-2180, Dec. 2022. | en_US |
ISSN | 0022-1899 | en_US |
URI | https://www.arca.fiocruz.br/handle/icict/63609 | |
Description | Collaborators: HPTN 083 Study Team: Michael Seisa, Yolanda Lie, William Meyer, Jeanne Marrazzo, Sheila Peel, Carole Wallis, Aida Asmelash, Eric Daar, James Rooney, Richard Clark. | en_US |
Sponsorship | This work was supported by the National Institute of Allergy and Infectious Diseases, Office of the Director, National Institutes of Health, the National Institute of Mental Health, the National Institute on Drug Abuse, and the Eunice Kennedy Shriver Institute for Child Health and Human Development (grant numbers UM1AI068619 to HIV
Prevention Trials Network Leadership and Operations Center, UM1AI068617 to HPTN Statistical and Data Management Center, and UM1AI068613 to HPTN Laboratory Center). ViiV Healthcare and Gilead Sciences donated trial medications and matching placebos, and ViiV Healthcare provided additional funding. | en_US |
Language | eng | en_US |
Publisher | University of Chicago Press | en_US |
Rights | open access | en_US |
Title | HIV RNA Screening Reduces Integrase Strand Transfer Inhibitor Resistance Risk in Persons Receiving Long-Acting Cabotegravir for HIV Prevention | en_US |
Type | Article | en_US |
DOI | 10.1093/infdis/jiac415 | |
Abstract | Background: The HPTN 083 trial demonstrated that long-acting cabotegravir (CAB-LA) was superior to tenofovir-disoproxil fumarate/emtricitabine for human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP). Integrase strand transfer inhibitor (INSTI) resistance-associated mutations (RAMs) were detected in some participants with HIV infection. We used a low viral load INSTI genotyping assay to evaluate the timing of emergence of INSTI RAMs and assessed whether HIV screening with a sensitive RNA assay would have detected HIV infection before INSTI resistance emerged. Methods: Single-genome sequencing to detect INSTI RAMs was performed for samples with viral loads <500 copies/mL from 5 participants with previously identified INSTI RAMs and 2 with no prior genotyping results. Results: Major INSTI RAMs were detected in all 7 cases. HIV RNA testing identified infection before major INSTI RAMs emerged in 4 cases and before additional major INSTI RAMs accumulated in 1 case. Most INSTI RAMs were detected early when the viral load was low and CAB concentration was high. Conclusions: When using CAB-LA PrEP, earlier detection of HIV infection with a sensitive RNA assay may allow for earlier treatment initiation with the potential to reduce INSTI resistance risk. Further studies are needed to evaluate the value and feasibility of HIV RNA testing with CAB-LA PrEP. | en_US |
Affilliation | Johns Hopkins University School of Medicine. Department of Pathology. Baltimore, Maryland, USA. | en_US |
Affilliation | Johns Hopkins University School of Medicine. Department of Pathology. Baltimore, Maryland, USA. | en_US |
Affilliation | University of Pittsburgh. Department of Medicine. Pittsburgh, Pennsylvania, USA. | en_US |
Affilliation | Johns Hopkins University School of Medicine. Department of Pathology. Baltimore, Maryland, USA. | en_US |
Affilliation | Johns Hopkins University School of Medicine. Department of Pathology. Baltimore, Maryland, USA / Johns Hopkins University School of Medicine. Department of Medicine. Baltimore, Maryland, USA. | en_US |
Affilliation | University of California. Department of Medicine. Los Angeles, California, USA. | en_US |
Affilliation | Fred Hutchinson Cancer Research Center. Seattle, Washington, USA. | en_US |
Affilliation | University of Pittsburgh. Department of Medicine. Pittsburgh, Pennsylvania, USA. | en_US |
Affilliation | FHI 360. Durham, North Carolina, USA. | en_US |
Affilliation | ViiV Healthcare. Research Triangle Park, North Carolina, USA. | en_US |
Affilliation | ViiV Healthcare. Research Triangle Park, North Carolina, USA. | en_US |
Affilliation | Prevention Science Program. Division of AIDS. National Institute of Allergy and Infectious Diseases. National Institutes of Health. Rockville, Maryland, USA. | en_US |
Affilliation | Asociación Civil Selva Amazónica. Iquitos, Peru. | en_US |
Affilliation | Asociación Via Libre. Lima, Peru. | en_US |
Affilliation | University of Cape Town. Institute of Infectious Disease and Molecular Medicine. Desmond Tutu HIV Centre. Cape Town, South Africa. | en_US |
Affilliation | Fred Hutchinson Cancer Research Center. Seattle, Washington, USA. | en_US |
Affilliation | University of North Carolina. Department of Medicine. Chapel Hill, North Carolina, USA. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil. | en_US |
Affilliation | University of California. Center for Clinical AIDS Research and Education. Los Angeles, California, USA. | en_US |
Subject | HIV | en_US |
Subject | HPTN | en_US |
Subject | INSTI | en_US |
Subject | Cabotegravir | en_US |
Subject | Injectable | en_US |
Subject | Integrase | en_US |
Subject | PrEP | en_US |
Subject | Prevention | en_US |
Subject | Resistance | en_US |
e-ISSN | 1537-6613 | |